WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the
10th anniversary of its initial listing on NASDAQ.
NeuroMetrix debuted on NASDAQ on July 22, 2004 as a medical device
company with unique technology that allowed nerve conduction studies,
previously the domain of specialist physicians, to be performed at the
point-of-care. This led to the creation of a new market as primary care
and other physicians expanded the scope of their services to include
nerve testing and patients benefitted from its convenience.
Reimbursement changes over the years eroded this market and NeuroMetrix
shifted its focus to the diabetes sector. During the past three years,
the Company has launched two important new products: NC-stat DPNCheck
which is a fast, accurate, quantitative test for diabetic peripheral
neuropathy, and SENSUS Pain Management which is a therapeutic device for
the treatment of chronic pain including painful diabetic neuropathy.
Today NeuroMetrix is widely viewed as an emerging business in the
fast-growing field of wearable health electronics. SENSUS is a good
example of products in this category.
"Our NASDAQ listing has been an important factor in our access to
capital markets and has provided orderly trading in our stock for
investors," said Shai Gozani, M.D., Ph.D., President and Chief Executive
Officer of NeuroMetrix. "We are very pleased with our long association
with NASDAQ."
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The Company has a major focus on diabetic neuropathies, which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has
been estimated at $14 billion in the United States. The Company markets
the SENSUS device for treating chronic pain, focusing on physicians
managing patients with neuropathic pain such as painful diabetic
neuropathy. The Company also markets DPNCheck®, which is a
rapid, accurate, and quantitative point-of-care test for peripheral
neuropathies such as diabetic neuropathy. This product is used to detect
neuropathies at an early stage and to guide treatment. For more
information, please visit http://www.SENSUSRx.com
or http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
